<DOC>
	<DOCNO>NCT02983214</DOCNO>
	<brief_summary>Investigation clinical efficacy safety dual antiplatelet therapy clopidogrel cilostazol versus clopidogrel alone prevent ischemic vascular event patient type 2 diabetes symptomatic peripheral arterial disease .</brief_summary>
	<brief_title>Diabetic Artery Obstruction : Possible Reduce Ischemic Events With Cilostazol ?</brief_title>
	<detailed_description>Cilostazol quinoline derivative selectively reversibly inhibit cellular cyclic adenosine monophosphate ( cAMP ) phosphodiesterase III , thus suppress cAMP degradation maintain high intracellular level . Through mechanism , cilostazol inhibits platelet aggregation , exert significant antiplatelet antithrombotic activity . Cilostazol also improve endothelial function exert anti-inflammatory , anti-atherogenic vasodilatory effect . Additionally , cilostazol inhibits equilibrative nucleoside transporter-1 ( ENT-1 ) responsible cellular uptake adenosine , reduce plasma concentration . Through mechanism , cilostazol maintains high extracellular adenosine concentration allow adenosine exert biological effect . Thus , cilostazol show potent antithrombotic activity , also prevent restenosis percutaneous coronary intervention ( PCI ) . Finally , cilostazol beneficial effect lipidemic profile reduce triglyceride level increase HDL-cholesterol . Clinical study show patient intermittent claudication , cilostazol increase walk distance . Based study , cilostazol administration combination antiplatelet drug ( clopidogrel aspirin ) recommend patient intertermittent claudication . Recent pharmacodynamic study demonstrate add cilostazol aspirin clopidogrel may represent effective way overcome high on-treatment platelet reactivity . Additionally , clinical study show addition cilostazol dual antiplatelet therapy aspirin clopidogrel ( triple antiplatelet therapy , TAPT ) patient acute coronary syndrome undergo PCI offer significant clinical benefit . This favorable effect cilostazol confirm recent meta-analysis include nine study total 2,179 patient undergoing PCI . Furthermore , clinical study show administration TAPT cilostazol reduces restenosis PCI . Finally , administration dual antiplatelet therapy cilostazol aspirin significantly reduce progression symptomatic intracranial arterial stenosis compare monotherapy aspirin . The aim The Diabetic artery Obstruction : possible Reduce Ischemic event Cilostazol ? ( DORIC ) trial investigate clinical efficacy safety dual antiplatelet therapy ( DAPT ) clopidogrel cilostazol versus clopidogrel alone prevent ischemic vascular eventsin patient type 2 diabetes ( DM2 ) symptomatic peripheral arterial disease ( PAD ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Patients age ≥50 year DM2 symptomatic PAD diagnose clinically ( accord Fontaine criterion , stage IIa IIb III ) measure ΑΒΙ . Congestive heart failure , history ventricular tachycardia , ventricular fibrillation multifocal ventricular extrasystole QTc prolongation . Patients atrial fibrillation take anticoagulant therapy patient history cardioembolic ischemic stroke hemorrhagic stroke . Patients history ( ≤ 12 month ) acute coronary syndrome receive dual antiplatelet therapy , patient receive monotherapy aspirin . Patients hepatic impairment ( childPugh staging , calibration ≥ 5 ) renal impairment ( creatinine clearance ≤ 30ml / min ) , recent peptic ulcer , history hypersensitivity cilostazol , cancer patient undergoing treatment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cilostazol</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Peripheral Artery Disease</keyword>
</DOC>